Medicines are a part of the solution

05.10.13 | By

IMS’ latest report, Declining Medicine Use and Costs: For Better or Worse, reasserts the value that medicines provide in improving patients’ health and saving money on future health care costs. It’s also a great example of how and why the life cycle of medicines works so well. 

Vendor Profile: The Antibody, The Scientist, and an Adorable Sheep; The Story of Abcam

05.10.13 | By

Last week I wrote about my experience at the US Chamber’s Small Business Summit, and noted that I would be profiling some smaller businesses who work with pharmaceutical manufacturing companies as vendors.

PhRMA Statement on FDA Benefit Risk Assessment Plan

WASHINGTON, D.C. (May 9, 2013) – Pharmaceutical Research and Manufacturers of America (PhRMA) Vice President of Scientific and Regulatory Affairs Sascha Haverfield, Ph.D., issued the following statement today on the Food and Drug Administration’s (FDA) Draft PDUFA V Implementation Plan: Structured Approach to Benefit-Risk Assessment in Drug Regulatory Decision Making:


PhRMA frequently hosts and participates in online and in-person events that delve into the science, policy and regulatory issues critical to biopharmaceutical innovation and patient access to medicines.

Biopharmaceutical Industry Pipeline panel discussion

Learn  about recent events:

Biopharmaceutical Scientists

05.08.13 | By

Edited 05.10.13

As an industry, we need to do a better job of telling our story – who we are, what we believe in, and why the work we are doing is so important.  If we don’t, we will continue to be misunderstood and the full value of innovative medicines may not be recognized. 

Merck Scientist Pioneered the Invention of More Than 40 Vaccines, Saving Millions of Lives

05.07.13 | By

In the (now famous) picture, a mumps-ridden Jeryl Hilleman screams at the camera while older sister Kristen cautiously holds the baby still enough to endure the prick of a needle held by their father, Merck vaccinologist Dr. Maurice Hilleman.  In the picture, Hilleman has the scowl of an anxious father heavy on his brow, and with good reason:  the cultures taken from baby Jeryl that March night in 1966 were later used by her father to develop the Measles, Mumps and Rubella (M.M.R.) vaccine, presently given to more than 95 percent of American children and saving millions of lives.

Ongoing Research in Leukemia & Lymphoma

05.07.13 | By

Blood cancers, such as leukemia and lymphoma, can affect anyone, including children. Each year, nearly 150,000 Americans are diagnosed with a blood cancer—accounting for about 9 percent of all new cancer diagnoses according to the American Cancer Society.

Translational Medicine

05.07.13 | By

A recent article in the Telegram discussed translation medicine, a discipline that tries to reduce the gaps between discoveries made in the research laboratory and their application in clinical practice.

The PFCD’s Mission – Improved Health, Lower Health Care Costs

05.06.13 | By

In a blog a couple of weeks ago, I summarized the many anti-chronic disease efforts PhRMA supports and explained why we’ve made those commitments.  High on the list of programs we back is the Partnership to Fight Chronic Disease (PFCD) and a recent statement by the Centers for Disease Control and Prevention explains why: 

Part D Helps Control Medicare Spending

05.06.13 | By

Last week the CMS Office of the Actuary, following legislatively proscribed duties, stated that actual and projected Medicare expenditures for 2011 through 2015 are low enough that they will not trigger the Independent Payment Advisory Board (IPAB) to recommend binding cuts to the Medicare program.


Subscribe to RSS - Opinion